Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASAQ and AL efficacy study for uncomplicated falciparum malaria in South Sudan
ACTRN12626000495325Phase 4Completed
- Sponsor
- Ministry of Health
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of artesunate, amodiaquine, artemether and lumefantrine in malaria and Falciparum malaria (PF) (2 arms), sponsored by Ministry of Health. Primary endpoint: Proportion of treatment failures. Started Jan 2024; status: completed.
02
Drugs
artesunateamodiaquineartemetherlumefantrine
03
Conditions
malariaFalciparum malaria (PF)
Beyond the preview
Go deeper on ACTRN12626000495325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626000495325.